2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

murine monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Peptides

29

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9948
    Alemtuzumab

    Campath-IH

    		 Apoptosis Cancer
    Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC), as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research .
    Alemtuzumab
  • HY-P99023
    Girentuximab
    1 Publications Verification

    G250; cG250

    		 Carbonic Anhydrase Cancer
    Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) .
    Girentuximab
  • HY-P99294
    Ganitumab
    1 Publications Verification

    AMG 479; Human Anti-IGF1R Recombinant antibody

    		 IGF-1R Cancer
    Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
    Ganitumab
  • HY-P9964
    Necitumumab

    11F8; IMC-11F8; LY3012211

    		 EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-108852
    Basiliximab

    CHI 621

    		 Interleukin Related Inflammation/Immunology Cancer
    Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation .
    Basiliximab
  • HY-P99379
    Nidanilimab (Nadunolimab)

    CAN04; Anti-IL-1RAP/IL-1R3 Reference antibody (nidanilimab)

    		 Interleukin Related Cancer
    Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .
    Nidanilimab (Nadunolimab)
  • HY-P99336
    Enlimomab

    BI-RR 0001; Anti-Human IL6 Recombinant antibody

    		 Integrin Neurological Disease Inflammation/Immunology
    Enlimomab (BI-RR 0001), a murine IgG2a monoclonal antibody to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. Enlimomab has anti-inflammatory effects, and can be used for stroke research .
    Enlimomab
  • HY-P99008
    Atibuclimab
    2 Publications Verification

    IC14

    		 Toll-like Receptor (TLR) Infection Neurological Disease Inflammation/Immunology
    Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
    Atibuclimab
  • HY-P0325
    V5 Epitope Tag Peptide TFA

    		Biochemical Assay Reagents Others
    V5 Epitope Tag Peptide TFA is a tag peptide derived from a small epitope present on the P and V proteins of the paramyxovirus of simian virus 5. V5 Epitope Tag Peptide TFA can be used for protein separation and purification, and competitive elution with target proteins .
    V5 Epitope Tag Peptide TFA
  • HY-P99732
    Minretumomab
    1 Publications Verification

    CC-49

    		 Mucin Cancer
    Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research .
    Minretumomab
  • HY-P99566
    Tenatumomab

    ST2146

    		 Transmembrane Glycoprotein Cancer
    Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach .
    Tenatumomab
  • HY-P99287
    Elsilimomab

    B-E8; Anti-IL-6 MAB B-E8

    		 Interleukin Related Inflammation/Immunology Cancer
    Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA) .
    Elsilimomab
  • HY-P99409
    Oregovomab

    Alt-2 monoclonal antibody; MAB-B43.13; Oregovamab

    		 Transmembrane Glycoprotein Cancer
    Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .
    Oregovomab
  • HY-P99707
    Lilotomab

    HH1

    		 Apoptosis Cancer
    Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity .
    Lilotomab
  • HY-P991618
    ST2485

    		Transmembrane Glycoprotein Cancer
    ST2485 is a monoclonal antitenascin antibody. ST2485 shows additivity in tenascin C binding in vitro as well as in a xenograft model. ST2485 binds human tenascin at an epitope partially shared with BC2. ST2485 cross-reacts with murine tenascin. ST2485 can be studied in antitumor research .
    ST2485
  • HY-P9937
    Arcitumomab

    IMMU-4

    		 Transmembrane Glycoprotein Cancer
    Arcitumomab is a murine anti-carcinoembryonic antigen (CEA) monoclonal antibody Fab’ fragment. Arcitumomab can be labeled with technetium-99m and can be used for single-photon emission computed tomography (SPECT) imaging .
    Arcitumomab
  • HY-P991608
    CTM01

    7F11C7

    		 Mucin Cancer
    CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer .
    CTM01
  • HY-P991601
    Anti-IL6 Antibody (MH166)

    		Interleukin Related Inflammation/Immunology
    Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
    Anti-IL6 Antibody (MH166)
  • HY-W775071A
    Sulcofuron

    		Insecticide Others
    Sulcofuron is a pesticide. Sulcofuron can be used for production of monoclonal murine anti-pesticide antibodies by in vitro immunisation .
    Sulcofuron
  • HY-P991600
    Anti-IL-6 Antibody (Chugai SK2)

    		Interleukin Related Inflammation/Immunology Cancer
    Anti-IL-6 Antibody (Chugai SK2) is a murine monoclonal antibody, targeting IL-6. Anti-IL-6 Antibody (Chugai SK2) can be used for inflammatory diseases and cancers research, such as rheumatoid arthritis (RA), crohn's disease (CD) and pancreatic, lung and colon cancer .
    Anti-IL-6 Antibody (Chugai SK2)
  • HY-P991947
    ELB041

    AFS98; TG3003

    		 c-Fms Inflammation/Immunology
    ELB041 (AFS98) is a rat monoclonal anti-murine c-fms antibody (IgG2a). AFS98 inhibits M-CSF–dependent colony formation and cell growth by blocking the binding of M-CSF to its receptor. AFS98 prevents development of fatty streaks in ApoE-deficient mice. ELB041 can be used for the research of atherosclerosis .
    ELB041
  • HY-P992053
    Anti-CD11a Antibody (MHM24)

    		Integrin Inflammation/Immunology
    Anti-CD11a Antibody (MHM24) is a monoclonal antibody targeting murine CD11a. Anti-CD11a Antibody (MHM24) binds to high-affinity (open) and low-affinity (closed) conformations of the αL subunit of LFA-1, and functionally blocks LFA-1-mediated interactions. Anti-CD11a Antibody (MHM24) blocks ICAM-1 binding to LFA-1-expressing cells. Anti-CD11a Antibody (MHM24) inhibits adhesion of high-affinity LFA-1-expressing cells to keratinocytes. Anti-CD11a Antibody (MHM24) inhibits PHA-induced lymphocyte proliferation. Anti-CD11a Antibody (MHM24) can be used for the research of inflammatory and autoimmune diseases. Recommend Isotype Controls: mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-CD11a Antibody (MHM24)
  • HY-P992430
    OI-3

    		Transmembrane Glycoprotein Radionuclide-Drug Conjugates (RDCs) Inflammation/Immunology Cancer
    OI-3 is a monoclonal antibody targeting CD146 (MCAM). OI-3 specifically binds to CD146 on the surface of human mesothelioma cells and undergoes endocytosis; both chimeric (chOI-3) and murine (mOI-3) variants possess this activity. When conjugated with 212Pb to form 212Pb-TCMC-OI-3, OI-3 acts as a cytotoxic agent that delivers α-emitting radionuclides to induce targeted cytotoxicity. OI-3 can be used in research related to malignant peritoneal mesothelioma .
    OI-3
  • HY-P992095
    Nofetumomab

    		CD20 Cancer
    Nofetumomab is an anti-human monoclonal antibody targeting CD20. Nofetumomab can be used for the research cancer .
    Nofetumomab
  • HY-P992172
    ADEL-Y01

    		Tau Protein Neurological Disease
    ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies .
    ADEL-Y01
  • HY-181916
    BXY-14

    		Toll-like Receptor (TLR) PD-1/PD-L1 Inflammation/Immunology Cancer
    BXY-14 is a TLR2 agonist and vaccine adjuvant. BXY-14 significantly downregulates the expression of intratumoral PD-L1 in mouse models. BXY-14 acts as a vaccine adjuvant to induce antibody responses. BXY-14 exhibits synergistic efficacy when combined with the anti-PD-L1 monoclonal antibody Atezolizumab (HY-P9904) in mouse models of melanoma, and prolongs overall survival. BXY-14 is applicable to research related to melanoma .
    BXY-14
  • HY-P991744
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)

    		CXCR Cancer
    Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma .
    Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
  • HY-183784
    P2X7R antagonist-1

    		P2X Receptor FAK MMP Cancer
    P2X7R antagonist-1 is an orally active P2X7 receptor antagonist with an IC50 of 3.57 μM. P2X7R antagonist-1 inhibits the proliferation, invasion and metastasis abilities of cancer cells. P2X7R antagonist-1 downregulates the expression of FAK and MMP-9. P2X7R antagonist-1 suppresses tumor growth and metastasis in a mouse breast cancer model. P2X7R antagonist-1 promotes the activation of CD4 and CD8 T cells. P2X7R antagonist-1 can be used in breast cancer-related research .
    P2X7R antagonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: